NCT05787496 · REGISTRY CONDITION SEARCH

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: TERMINATED
Registry last update: 2026-01-28

This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

To Evaluate the Frequency, Duration, and Severity of Treatment-emergent Adverse Events [Safety and Tolerability].

→

outcome · POSTED

To Evaluate Dose-limiting Toxicities (DLTs) of NC525.

→

outcome · POSTED

To Evaluate the Clinical Benefit of NC525 by Assessing Objective Response (OR).

→

outcome · POSTED

To Evaluate the Clinical Benefit of NC525 by Assessing Event-free Survival (EFS).

→

outcome · POSTED

To Evaluate the Clinical Benefit of NC525 by Assessing Overall Survival (OS).

→

outcome · POSTED

Assessment of Time to Achieve Response, Defined as CR, CRi, or CRh

→

outcome · POSTED

Maximum Observed Serum Concentration (Cmax) of NC525

→

outcome · POSTED

Terminal Half-life (t1/2) of NC525

→

outcome · POSTED

Area Under the Serum Concentration Versus Time Curve (AUC) of NC525

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. The subject is willing to provide written informed consent for the trial. 2. Be ≥ 18 years of age on the day of signing informed consent. 3. Subject has one of the following Myeloid Neoplasms determined by pathology review at the treating institution: 1. Relapsed or Refractory AML, Note: Active, relapsed, or refractory AML is defined as any one of the following: * Primary induction failure, or (PIF) after 2 or more cycles of therapy, * First early relapse after a remission duration of fewer than 6 months, * Relapse refractory to salvage combination chemotherapy second or subsequent relapse, or * Relapsed or refractory AML with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood. 2. Relapsed or Refractory Myelodysplastic syndrome (MDS) after prior hypomethylating agents. Note: Subject must have sub-type MDS-EB2 with 10-19% blasts by bone marrow biopsy or aspirate. 3. Relapsed or Refractory Chronic myelomonocytic leukemia (CMML) with progressive disease or lack of response to hypomethylating agents 4. A male subject must agree to use approved contraception (based on institutional guidelines) and refrain from sperm donation or expecting to father a child, from Screening through the treatment period and for at least 90 days after the last dose of study treatment. 5. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP); 2. A WOCBP agrees to follow approved contraceptive guidance (based on institutional guidelines) from Screening through the treatment period and for at least 90 days after the last dose of study treatment. 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 7. Life expectancy greater than or equal to 12 weeks as judged by the Investigator. 8. Have adequate organ function as defined in the protocol. Exclusion Criteria: 1. Has a diagnosis of acute promyelocytic leukemia (M3, APL), accelerated phase or blast crisis of chronic myeloid leukemia. 2. History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. 3. Patients with active Central Nervous System (CNS) involvement (such as leukemic infiltration, blast in the spinal fluid, or subjects with extramedullary disease). 4. A WOCBP who has a positive pregnancy test (within 72 hours) prior to treatment. 5. History or evidence of any other clinically significant disorder, condition or disease (e.g., symptomatic congestive heart failure, unstable angina pectoris, symptomatic myocardial infection, uncontrolled cardiac arrhythmia, pericardial disease or heart failure New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity and in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion. 6. Chronic respiratory disease or any other medical condition that requires continuous oxygen that in the opinion of the Investigator, would adversely affect his/her participation in this study. 7. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. 8. Is currently participating in or has participated in a study of the following prior to the first dose of study treatment: 1. An investigational biologic or an investigational device within 4 weeks or 5 half-lives (whichever is longer); 2. An investigational oral agent within 2 weeks or 5 half-lives (whichever is shorter). 9. Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior chemotherapy, immunotherapy and radiation therapy) and/or complications from interventions before starting therapy. 10. Has previously had an allogeneic solid organ transplant. 11. Autologous HSCT within 6 weeks before the start of study treatment. 12. Allogeneic HSCT within 6 months before the start of study treatment. 13. Any active acute or chronic graft-versus-host disease (GvHD), grade 2-4, or active chronic GvHD requiring systemic treatment. 14. Any systemic therapy (e.g. calcineurin inhibitors (CNI), steroids, etc.) against GvHD within 4 weeks before the start of study treatment. 15. Any Grade ≥ 2 persistent non-hematological toxicity related to allogeneic transplant, such as those requiring systemic immunosuppressive therapy. 16. Previous CAR-T therapy. 17. Known concurrent malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry after treatment with curative intent. 18. Has severe hypersensitivity (≥ Grade 3), known allergy or reaction to Immunoglobulins or NC525, and/or any of their excipients. 19. Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate anti-infection treatment at the time of eligibility confirmation. 20. Has a known history of HIV infection. 21. Has a known active chronic hepatitis B infection or chronic hepatitis C infection with the exception of those with an undetectable viral load within 3 months. 22. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate, in the opinion of the treating investigator. 23. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Subjects received NC525 IV at 2mg/kg bi-weekly (Q2W) for Cycles 1-6, followed by every 4 weeks (Q4W) thereafter.
intervention Names
Drug: NC525
label
2mg/kg NC525
type
EXPERIMENTAL
description
Subjects received NC525 IV at 2.5mg/kg weekly (QW) until overall response (e.g., CR, CRh, or CRi) is achieved, at which time they may switch to Q2W dosing. Subjects in Cohort 2 initially received 3mg/kg weekly but dose was reduced to 2.5mg/kg weekly at FDA request due to change in dosing frequency from Q2W to QW.
intervention Names
Drug: NC525
label
2.5mg/kg NC525
type
EXPERIMENTAL
description
Subjects received NC525 IV at 4.5mg/kg weekly (QW) until overall response (e.g., CR, CRh, or CRi) is achieved, at which time they may switch to Q2W dosing.
intervention Names
Drug: NC525
label
4.5mg/kg NC525
type
EXPERIMENTAL
description
Subjects received NC525 IV at 9mg/kg weekly (QW) until overall response (e.g., CR, CRh, or CRi) is achieved, at which time they may switch to Q2W dosing.
intervention Names
Drug: NC525
label
9mg/kg NC525
type
EXPERIMENTAL
description
Subjects received NC525 IV at 13.5mg/kg weekly (QW) until overall response (e.g., CR, CRh, or CRi) is achieved, at which time they may switch to Q2W dosing.
intervention Names
Drug: NC525
label
13.5mg/kg NC525
type
EXPERIMENTAL
description
Subjects received NC525 IV at 18mg/kg weekly (QW) until overall response (e.g., CR, CRh, or CRi) is achieved, at which time they may switch to Q2W dosing.
intervention Names
Drug: NC525
label
18mg/kg NC525
type
EXPERIMENTAL

interventions

arm Group Labels
13.5mg/kg NC525
18mg/kg NC525
2.5mg/kg NC525
2mg/kg NC525
4.5mg/kg NC525
9mg/kg NC525
description
Monoclonal antibody specific for LAIR-1
name
NC525
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 28
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Toxicity grading per NCI CTCAE v5.0.
measure
To Evaluate the Frequency, Duration, and Severity of Treatment-emergent Adverse Events [Safety and Tolerability].
time Frame
Up to 23 months
description
Toxicity grading per NCI CTCAE v5.0.
measure
To Evaluate Dose-limiting Toxicities (DLTs) of NC525.
time Frame
Up to 56 days

secondary Outcomes

description
Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.
measure
To Evaluate the Clinical Benefit of NC525 by Assessing Objective Response (OR).
time Frame
Until disease progression, up to 23 months
description
Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.
measure
To Evaluate the Clinical Benefit of NC525 by Assessing Event-free Survival (EFS).
time Frame
Until disease progression, up to 23 months
description
Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.
measure
To Evaluate the Clinical Benefit of NC525 by Assessing Overall Survival (OS).
time Frame
Time until death, up to 23 months
description
Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.
measure
Assessment of Time to Achieve Response, Defined as CR, CRi, or CRh
time Frame
Cycle 1 Day 1 to day remission is achieved, up to 23 months (each cycle is 28 days)
description
To evaluate the maximum observed serum concentration (Cmax) of NC525. The values reported are Cmax at Cycle 2 Day 1.
measure
Maximum Observed Serum Concentration (Cmax) of NC525
time Frame
During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)
description
To evaluate the Terminal Half-life (t1/2) of NC525.
measure
Terminal Half-life (t1/2) of NC525
time Frame
During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days), Cycle 1 reported
description
To evaluate area under the serum concentration versus time curve (AUC) of NC525
measure
Area Under the Serum Concentration Versus Time Curve (AUC) of NC525
time Frame
During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days), Cycle 1 reported

Full study description

brief Summary: This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-ddbc3b282f8dfd4d5864
requested nct id
NCT05787496
primary nct id
NCT05787496
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
payload sha256
5404ab6382fa3c3010c3184f294fc17114ef005e852a2c9c710df8fab03cb117
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-ddbc3b282f8dfd4d5864
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT05787496
occurrences
context exact
NCT05787496
end
11
exact text
NCT05787496
start
0
offset unit
unicode_code_points
query cond
Juvenile Myelomonocytic Leukemia
query disease state id
ds-juvenile-myelomonocytic-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
source json pointer
/studies/56/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
9124f7b44628f74befec07b516afa8b95b1ba3f58a61855f957f5427eec40487
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice